Fingolimod, sold under the brand name Gilenya, is an immunomodulating medication, used for the treatment of multiple sclerosis. [4] Fingolimod is a sphingosine-1-phosphate receptor …

2024年6月20日 · Gilenya is used to prevent episodes of symptoms and slow the worsening of disability in adults and children 10 years of age and older with relapsing-remitting forms …

芬戈莫德是一种神经鞘氨醇1-磷酸受体调节剂适用于复发性多发性硬化症患者的治疗减少临床加重的频数和延缓身体残疾的积蓄。 (1) 剂量和给药方法. （1）推荐剂量：0.5 mg口服每天1次， …

2019年7月20日 · 捷灵亚® 是第一种、也是唯一一种同时覆盖多发性硬化症儿童、青少年和成人患者的疾病修正治疗（DMT）方法。 捷灵亚®也于2018年被国家药品监督管理局药品审评. 2019 …

GILENYA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing …

Find patient medical information for Gilenya oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), …

2022年4月23日 · Learn about side effects, uses, costs, and more of Gilenya (fingolimod). It’s a prescription drug that treats multiple sclerosis in adults and some children.

2019年7月21日 · 诺华制药（中国）近日宣布，国家药品监督管理局批准捷灵亚® （Gilenya，通用名：fingolimod，芬戈莫德）用于10岁及以上患者复发型多发性硬化（RMS）的治疗。

芬戈莫德被纳入国家第一批临床急需药品名单，是目前中国乃至全球唯一具有10岁及以上儿童和成人多发性硬化适应症的DMT药物，能有效干预外周炎性病变，显著降低临床复发与病灶新增或 …